Clinical Trial Update: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase II study evaluating rituximab plus venetoclax as frontline therapy for marginal zone lymphoma, with the trial curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING